AbbVie Inc.

ABBV remains in a strong multi-month uptrend and is pressing its 52-week high, well above the 200-day moving average at 221.26. The setup still favors trend followers, with the stock extended from its low of 178.57 and trading above the 50-day average at 214.78.

Street sentiment stays constructive: 28 buys, 12 holds, and 1 sell, with a Buy consensus and an average target around 258 versus the current share price near 255.6. Recent calls have mostly reiterated positive views, while targets have been nudged higher by Canaccord, Piper Sandler, and Morgan Stanley.

The next print comes after a mixed but still solid beat streak: 6 of the last 7 quarters topped EPS estimates, with the latest quarter missing by 0.7%. Analysts still look for sharp long-term earnings growth, so shareholders should watch whether Skyrizi and Rinvoq can keep offsetting mature franchises.

No notable discretionary insider buying or selling. Recent activity is dominated by award grants and one in-kind transaction, including director awards on 2026-05-08 and 2026-03-31, plus a controller in-kind transaction on 2026-02-27; those are not the same as open-market conviction trades.

Profitability is strong, led by a 72.0% gross margin and a 32.16% operating margin, with ROE at 62.25%. Cash generation is robust at $20.24 billion of free cash flow, but leverage remains heavy with $69.07 billion of total debt against $5.26 billion of cash.

ABBV screens as a premium large-cap pharma name with a 25.08 P/E and a 4.52% FCF yield, reflecting quality and cash flow rather than bargain pricing. Its growth mix is stronger than many mature drug peers, but the balance sheet is more levered than the cleanest names in the group.